Bio Marc EN

Marc Le Bozec

55 y/o

Marc started as a consultant in organizational performance (Bossard Consultants) a further in strategy (Arthur D. Little). He incepted his first biotech company, BioProtein Technologies, back in 1998. Such company, dedicated to the manufacturing of biological drugs, was instrumental in the commercialization of a recombinant clotting factor for haemophilia. Marc joined Cellectis back in 2006 as a CFO and made it public on Paris stock market early 2007. He raised €120 million on behalf of Cellectis and paved the way for its future listing on Nasdaq. Marc was then a CEO at CYTOO, a biotech company based in the French Alps, from 2013 until 2015. He deeply modified its business model and prepared it to become a profitable company. He refinanced the company by himself with the support of the Chairman and some friends he gathered over the 2016-2018 period leading to a highly profitable organization.
Marc launched a UCITS late 2014 at Financière Arbevel, a Parisian boutique and further on a private equity fund up to ca. €40 million (first closing late 2018 and second closing in January 2020). Marc invested in 11 companies including 10 French ones and succeeded in exiting two of them during his tenure (TransCure bioServices sold to Cathay Capital with a 4x return early 2022 and Impacts sold to GE Healthcare with a 2x return early 2023).

Since mid-2023 Marc has been an advisor and a director for series of companies in the life sciences sector. Marc is graduated from HEC (92).